Pages that link to "Q39873892"
Jump to navigation
Jump to search
The following pages link to Progression of RAS-mutant leukemia during RAF inhibitor treatment (Q39873892):
Displaying 50 items.
- The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib (Q26744335) (← links)
- The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer (Q26747247) (← links)
- MEK and PI3K inhibition in solid tumors: rationale and evidence to date (Q26775573) (← links)
- Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma (Q26795510) (← links)
- PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms (Q26862544) (← links)
- Pathways and therapeutic targets in melanoma (Q26865736) (← links)
- Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond (Q27026323) (← links)
- RAF inhibitors that evade paradoxical MAPK pathway activation (Q27702299) (← links)
- Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients (Q27853121) (← links)
- Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease (Q28240576) (← links)
- Kinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation Cycle (Q28554490) (← links)
- MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition (Q30539640) (← links)
- Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion (Q33593231) (← links)
- Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression (Q33604228) (← links)
- Diffuse Cystic Lung Disease. Part I. (Q33722950) (← links)
- Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies (Q34341465) (← links)
- Development of synthetic lethality anticancer therapeutics (Q34380368) (← links)
- BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. (Q34393208) (← links)
- Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor (Q34484174) (← links)
- Differential and limited expression of mutant alleles in multiple myeloma (Q34508343) (← links)
- Drug safety evaluation of vemurafenib in the treatment of melanoma. (Q34653547) (← links)
- Paradoxical MAPK-activation in response to treatment with tyrosine kinase inhibitors in CML: flow cytometry loses track (Q34663279) (← links)
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma (Q35136819) (← links)
- Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition (Q35140015) (← links)
- BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia (Q35140116) (← links)
- Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. (Q35146078) (← links)
- Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy (Q35569132) (← links)
- Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma (Q35611909) (← links)
- (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges (Q35898282) (← links)
- Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors (Q36342842) (← links)
- RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies (Q36398735) (← links)
- The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock (Q36846723) (← links)
- Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker (Q36868328) (← links)
- Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval (Q36871001) (← links)
- Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. (Q36934327) (← links)
- Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells (Q36961746) (← links)
- In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors (Q37365693) (← links)
- Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor (Q37443583) (← links)
- Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer (Q37451255) (← links)
- Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation (Q37482888) (← links)
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma (Q37528285) (← links)
- Resistance to RAF inhibitors revisited (Q37625751) (← links)
- Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications (Q37632230) (← links)
- Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma (Q37697778) (← links)
- Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors (Q37705185) (← links)
- Developing melanoma therapeutics: overview and update (Q38081406) (← links)
- Update on the targeted therapy of melanoma. (Q38082713) (← links)
- Combining cancer immunotherapy and targeted therapy (Q38096565) (← links)
- That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. (Q38104439) (← links)
- Skin toxicity of targeted cancer agents: mechanisms and intervention. (Q38125504) (← links)